You are viewing an incomplete version of our website. Please click to reload the website as full version.

Browse our anti-BRAF (BRAF) Antibodies

Full name:
anti-V-Raf Murine Sarcoma Viral Oncogene Homolog B1 Antibodies (BRAF)
On www.antibodies-online.com are 393 V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) Antibodies from 24 different suppliers available. Additionally we are shipping BRAF Proteins (29) and BRAF Kits (7) and many more products for this protein. A total of 451 BRAF products are currently listed.
Synonyms:
9930012E13Rik, AA120551, AA387315, AA473386, B-raf, B-RAF1, Braf, Braf-2, BRAF1, Braf2, C-RMIL, C87398, C230098H17, D6Ertd631e, HYPT11, NS7, RAFB1, RMIL, sierrabraf, Sm-E, SME
list all antibodies Gene Name GeneID UniProt
BRAF 109880 P28028
BRAF 6635 P62304
BRAF 114486  

Show all species

Show all synonyms

Most Popular Reactivities for anti-BRAF (BRAF) Antibodies

Select your species and application

anti-Mouse (Murine) BRAF Antibodies:

anti-Human BRAF Antibodies:

anti-Rat (Rattus) BRAF Antibodies:

All available anti-BRAF Antibodies

Go to our pre-filtered search.

Top referenced anti-BRAF Antibodies

  1. Human Polyclonal BRAF Primary Antibody for EIA - ABIN358444 : Loewe, Kittler, Fischer, Faé, Wolff, Petzelbauer: BRAF kinase gene V599E mutation in growing melanocytic lesions. in The Journal of investigative dermatology 2004 (PubMed)
    Show all 5 references for ABIN358444

  2. Human Polyclonal BRAF Primary Antibody for EIA, IHC (p) - ABIN4620503 : Yamaguchi, Wallace, Magenheimer, Hempson, Grantham, Calvet: Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. in The Journal of biological chemistry 2004 (PubMed)
    Show all 5 references for ABIN4620503

  3. Human Polyclonal BRAF Primary Antibody for EIA - ABIN358356 : Frattini, Ferrario, Bressan, Balestra, De Cecco, Mondellini, Bongarzone, Collini, Gariboldi, Pilotti, Pierotti, Greco: Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. in Oncogene 2004 (PubMed)
    Show all 5 references for ABIN358356

  4. Human Polyclonal BRAF Primary Antibody for EIA - ABIN358344 : Tsavachidou, Coleman, Athanasiadis, Li, Licht, Olson, Weber: SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant. in Cancer research 2004 (PubMed)
    Show all 5 references for ABIN358344

  5. Human Polyclonal BRAF Primary Antibody for EIA - ABIN358271 : Gear, Williams, Kemp, Roberts: BRAF mutations in conjunctival melanoma. in Investigative ophthalmology & visual science 2004 (PubMed)
    Show all 5 references for ABIN358271

  6. Human Polyclonal BRAF Primary Antibody for EIA, IHC (p) - ABIN360131 : Hingorani, Jacobetz, Robertson, Herlyn, Tuveson: Suppression of BRAF(V599E) in human melanoma abrogates transformation. in Cancer research 2003 (PubMed)
    Show all 3 references for ABIN360131

  7. Human Polyclonal BRAF Primary Antibody for DB - ABIN389897 : Duan, Cobb: Calcineurin increases glucose activation of ERK1/2 by reversing negative feedback. in Proceedings of the National Academy of Sciences of the United States of America 2010 (PubMed)
    Show all 3 references for ABIN389897

  8. Human Polyclonal BRAF Primary Antibody for IHC (p), WB - ABIN392248 : Davies, Bignell, Cox, Stephens, Edkins, Clegg, Teague, Woffendin, Garnett, Bottomley, Davis, Dicks, Ewing, Floyd, Gray, Hall, Hawes, Hughes, Kosmidou, Menzies, Mould, Parker, Stevens, Watt, Hooper et al.: Mutations of the BRAF gene in human cancer. ... in Nature 2002 (PubMed)
    Show all 3 references for ABIN392248

  9. Human Polyclonal BRAF Primary Antibody for EIA, IHC (p) - ABIN360136 : Lee, Yoo, Soung, Kim, Park, Kim, Lee, Park, Cho, Kim, Ko, Kim, Nam, Lee, Lee: BRAF mutations in non-Hodgkin's lymphoma. in British journal of cancer 2003 (PubMed)
    Show all 3 references for ABIN360136

More Antibodies against BRAF Interaction Partners

Xenopus laevis V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) interaction partners

  1. BRAF alternative splicing is differentially regulated in vertebrates. Exon 9b is present in all vertebrates, including Xenopus, but exon 8b is present only in eutherians.

Zebrafish V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) interaction partners

  1. Gene expression studies nominated TWIST2 (show TWIST2 Antibodies) as a key effector downstream of BRAF.

  2. BRAF alternative splicing is differentially regulated in vertebrates. Exon 9b is present in all vertebrates, including Danio rerio, but exon 8b is present only in eutherians.

  3. BRAF activation is sufficient for f-nevus formation, and is among the primary events in melanoma development.

Chimpanzee V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) interaction partners

  1. BRAF alternative splicing is differentially regulated in rodent and primates. Exon 9b is present in vertebrates but exon 8b is present only in eutherians.

Mouse (Murine) V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) interaction partners

  1. A- and B-Raf ablation in chondrocytes does not alter skeletal development, whereas ablation of C-Raf decreases hypertrophic chondrocyte apoptosis and impairs vascularization of the growth plate. However, ablation of C-Raf does not impair phosphate-induced ERK1/2 phosphorylation in vitro, but leads to rickets by decreasing VEGF protein stability.

  2. these contrasting signatures precisely match those proposed to confer bias toward Hras (show HRAS Antibodies)(CAA61CTA) versus Braf(GTG636GAG) mutations in the original tumor sets. Our findings highlight a novel mechanism whereby exposure history acts through strand-biased mutagenesis to specify activation of preferred oncogenes

  3. these results suggest that the activation of 5-HT1D receptors selectively enhanced IA via the Gbetagamma of the Go-protein, PKA, and the sequential B-Raf (show SNRPE Antibodies)-dependent p38 MAPK (show MAPK14 Antibodies) signaling cascade.

  4. BRAF V600E inhibition stimulates AMP-activated protein kinase (show PRKAA2 Antibodies)-mediated autophagy in colorectal cancer cells.

  5. these data confirm the existence of a negative feedback pathway by which BRAF protein stability is regulated by ERK (show EPHB2 Antibodies).

  6. coexpression of BRAF(V600E) and KRAS(G12D) in early tumorigenesis leads to negative selection due to oncogene (show RAB1A Antibodies)-induced senescence

  7. findings suggest that targeting ErbB-3 (show ERBB3 Antibodies) receptors could represent an effective therapeutic approach in BRAF-V600E mutant colon cancer

  8. Atg7 (show ATG7 Antibodies) Overcomes Senescence and Promotes Growth of BrafV600E-Driven Melanoma

  9. Cotargeting is the treatment for mutant RAF (show RAF1 Antibodies)/MEK (show MDK Antibodies)/ERK (show EPHB2 Antibodies) and NF-kB pathways to treat mutant BRAF melanomas.

  10. The CM cell lines, as well as the tumor xenografts and their metastases, were positive for the melanoma markers HMB-45, S100B (show S100B Antibodies), and MART-1 (show RTL1 Antibodies). Two cell lines and their corresponding xenografts carried a BRAF mutation, the third showed an NRAS (show NRAS Antibodies) mutation.

Human V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) interaction partners

  1. The patients with traditional serrated adenoma showed KRAS and BRAF mutations in 58.4 and 8.3% of cases, respectively. Mutations of these genes were absent. The study revealed that the subtypes of serrated adenomas substantially differ by sex, age, localization, and molecular genetic characteristics

  2. r-BRAF are very uncommon in papillary thyroid carcinomas (PTC (show F9 Antibodies)) and are found almost exclusively in PTC (show F9 Antibodies) with low-risk clinicopathological features.

  3. (V600)BRAF switches on a metabolic reprogramming in melanoma cells, leading to a decreased OXPHOS activity and increased glycolytic ATP, lactate, HIF-1alpha (show HIF1A Antibodies) and MCT4 (show SLC16A4 Antibodies) levels.

  4. Data show that the expression of Interleukin-8 (IL-8 (show IL8 Antibodies)) and connective tissue growth factor (CTGF (show CTGF Antibodies)) was significantly reduced by treatment with vemurafenib and trametinib in (V600E)BRAF protein melanoma cells.

  5. The authors find that the interaction between sB-Raf (show RAF1 Antibodies) and the Hsp90 chaperone (show HSP90 Antibodies) system is based on contacts with the M domain of Hsp90 (show HSP90 Antibodies), which contributes in forming the ternary complex with Cdc37 (show CDC37 Antibodies) as long as the kinase is not stabilized by nucleotide.

  6. Data show that BRAF inhibitor (BRAFi) treatment failed to affect Nodal protein levels in melanoma tissues.

  7. BRAF V600E mutation is associated with cerebellar pilocytic astrocytoma recurring as a ganglioglioma.

  8. findings suggest an association of BRAF-V600E with parameters of a more aggressive behaviour of ameloblastoma

  9. Dabrafenib showed clinical activity in BRAF(V600E)-positive NSCLC. Our findings suggest that dabrafenib could represent a treatment option for a population of patients with limited therapeutic options

  10. BRAF(V600E)-mediated MEK (show MAP2K1 Antibodies)/ERK (show EPHB2 Antibodies) activation can upregulate MCL-1 (show MCL1 Antibodies) by phosphorylation/stabilization to confer apoptosis resistance that can be reversed by MCL-1 (show MCL1 Antibodies) antagonism combined with cobimetinib, suggesting a novel therapeutic strategy against BRAF(V600E)-mutant CRCs.

Horse (Equine) V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) interaction partners

  1. BRAF alternative splicing is differentially regulated in rodent and primates. Exon 9b is present in vertebrates but exon 8b is present only in eutherians.

BRAF Antigen Profile

Antigen Summary

This gene encodes a protein belonging to the raf/mil family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene are associated with cardiofaciocutaneous syndrome, a disease characterized by heart defects, mental retardation and a distinctive facial appearance. Mutations in this gene have also been associated with various cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, non-small cell lung carcinoma, and adenocarcinoma of lung. A pseudogene, which is located on chromosome X, has been identified for this gene.

Alternative names and synonyms associated with BRAF

  • v-raf murine sarcoma viral oncogene homolog B (braf) antibody
  • v-raf murine sarcoma viral oncogene homolog B1 (braf) antibody
  • v-raf murine sarcoma viral oncogene homolog B1 (BRAF) antibody
  • v-raf murine sarcoma viral oncogene homolog B1 (LOC100219601) antibody
  • Braf transforming gene (Braf) antibody
  • Braf transforming gene, related sequence 1 (Braf-rs1) antibody
  • small nuclear ribonucleoprotein polypeptide E (SNRPE) antibody
  • v-raf murine sarcoma viral oncogene homolog B (BRAF) antibody
  • v-raf murine sarcoma viral oncogene homolog B (Braf) antibody
  • 9930012E13Rik antibody
  • AA120551 antibody
  • AA387315 antibody
  • AA473386 antibody
  • B-raf antibody
  • B-RAF1 antibody
  • Braf antibody
  • Braf-2 antibody
  • BRAF1 antibody
  • Braf2 antibody
  • C-RMIL antibody
  • C87398 antibody
  • C230098H17 antibody
  • D6Ertd631e antibody
  • HYPT11 antibody
  • NS7 antibody
  • RAFB1 antibody
  • RMIL antibody
  • sierrabraf antibody
  • Sm-E antibody
  • SME antibody

Protein level used designations for BRAF

B-Raf , serine/threonine protein kinase BRAF , v-raf murine sarcoma viral oncogene homolog B1 , serine/threonine-protein kinase B-raf , serine/threonine-protein kinase B-raf-like , B-Raf proto-oncogene serine/threonine-protein kinase (p94) , proto-oncogene B-Raf , sm protein E , small nuclear ribonucleoprotein E , snRNP-E , 94 kDa B-raf protein , murine sarcoma viral (v-raf) oncogene homolog B1 , B-raf protein , B-Raf proto-oncogene serine/threonine-protein kinase , proto-oncogene c-Rmil , rmil serine/threonine-protein kinase , serine/threonine kinase , serine/threonine-protein kinase Rmil

GENE ID SPECIES
398973 Xenopus laevis
403065 Danio rerio
463781 Pan troglodytes
100219601 Taeniopygia guttata
100442288 Pongo abelii
109880 Mus musculus
110709 Mus musculus
6635 Homo sapiens
673 Homo sapiens
114486 Rattus norvegicus
536051 Bos taurus
475526 Canis lupus familiaris
396239 Gallus gallus
100065760 Equus caballus
Selected quality suppliers for anti-BRAF (BRAF) Antibodies
Did you look for something else?